The Latest Breaking News on Pharma

Synopsys, Inc. (NASDAQ:SNPS) shares are trading lower Wednesday after the company reported worse-than-expected financial results and issued fourth quarter adjusted earnings per share guidance below estimates on Tuesday after the market closed. Also, the company cut its fiscal-year 2025 adjusted earnings per share guidance below estimates.

New blow to UK’s key life science sector as industry body says country is losing ground on investment and research

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.

U.S. stocks were mixed, with the Nasdaq Composite gaining over 150 points on Monday.

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga’s Edge Stock Rankings.

Billionaire entrepreneur Mark Cuban, in a series of posts on the social media platform X early Monday morning, launched a scathing critique of the U.S. prescription drug industry, accusing large wholesalers and Pharmacy Benefit Managers (PBMs) of creating a “stranglehold” on pricing through opaque, anti-competitive practices.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Investors are increasingly looking to biotechnology companies for potential breakthroughs and profitable returns, as the sector shows resilience and growth amid broader market volatility. Within this landscape, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is capturing attention with its promising drug portfolio and financial performance.